Close
Novotech
Jabsco PureFlo 21 Single Use

Berry Global Underlines Its Commitment to South East Asia Region

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.

CMC Bottleneck in Drug Development and IND Delays

Ask any experienced biopharma program manager what derails an IND filing most often, and the answer is rarely surprising: it is CMC. Not insufficient efficacy data, not toxicology surprises CMC. This article examines why Chemistry, Manufacturing, and Controls continues to be the most underestimated risk in early drug development, and what program leaders can do about it.
- Advertisement -

Berry Global will demonstrate its commitment to delivering innovative, patient-centric packaging, dispensing solutions, and drug delivery devices for India and the South Asia region on the company’s stand at this year’s CPHI India exhibition.

Berry will showcase a wide range of products from its extensive portfolio, including bottles and caps, ophthalmic solutions, nasal and throat sprays, vials, dry powder inhalers (DPIs), and pressurized metered dose inhalers (pMDIs). Among these products will be the company’s latest advanced solutions for enhanced usability and administration safety, next generation digitalisation for medical devices and primary packaging, and circular design.

Many of the innovative products being shared at CPHI are produced at the company’s new factory and Centre of Excellence in Bangalore, India. The new location has both created local jobs and improved regional and global access to advanced healthcare solutions, providing customers with the necessary volume to support the forecasted growth for Asia’s domestic healthcare market.

“The Asia market is hugely important to Berry, as is evidenced by our ongoing investment in the region,” said Ramprakash Rai, Sales Director at Berry Global. “Our participation at CPHI India therefore provides the ideal opportunity to show the breadth of our products adapted to this exponential market, as we help our customers to Do Better by Dosing Better.”

“In particular, these solutions underline our abilities in developing solutions that enhance the user experience, improve disease management, and minimise environmental impact. We look forward to discussing customers’ specific requirements during CPHI India”
Berry is recognised as one of the global leaders in pharmaceutical packaging and dispensing, with over 25 healthcare-focused, ISCC PLUS-certified sites worldwide that enable the company to offer international and localised support for customers of all sizes. The company provides bespoke and standard solutions to help customers meet their unique product requirements and sustainability objectives.

Latest stories

Related stories

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.

CMC Bottleneck in Drug Development and IND Delays

Ask any experienced biopharma program manager what derails an IND filing most often, and the answer is rarely surprising: it is CMC. Not insufficient efficacy data, not toxicology surprises CMC. This article examines why Chemistry, Manufacturing, and Controls continues to be the most underestimated risk in early drug development, and what program leaders can do about it.

The Hidden Cost of Licensing in Biologic Drug Development

Royalties, milestone payments, and license fees are often treated as the cost of doing business in biopharma. But for early-stage biotech companies building toward an IND, these obligations can quietly reshape financial models, complicate investor conversations, and create downstream deal terms that are difficult to unwind. Here is what founders need to know.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »